12:00 AM
 | 
Oct 04, 1999
 |  BC Week In Review  |  Company News  |  Deals

Cell Pathways, Rhone-Poulenc Rorer deal

The companies will conduct clinical trials evaluating the combination of CLPA's Aptosyn exisulind, a selective apoptosis inducer,...

Read the full 65 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >